Kornimate/medical-research-clean huggingface dataset:
effects of comedy therapy on anxiety and vital signs in transplant recipients

Conditions: Liver Transplant; Complications; Stress; Care Acceptor, Health

Summary: this study was conducted to investigate the effects of watching excerpts from classical turkish comedy films on pre-transplant anxiety levels and vital signs in liver transplant recipients. h1-0: watching classical turkish comedy films has no effect on preoperative anxiety in liver transplant recipients. h1-1: watching classical turkish comedy films reduces preoperative anxiety in liver transplant recipients. h2-0: watching classical turkish comedy films has no effect on preoperative vital signs in liver transplant recipients. h2-1: watching classical turkish comedy films has a positive effect on preoperative vital signs in liver transplant recipients.

intervention group: a patient introduction form and a state anxiety scale will be applied as a pre-test before transplant surgery, and vital signs will be checked. patients will be shown 10-minute turkish comedy films prepared by researchers before transplant surgery. after the intervention, vital signs will be checked as a post-test and a state anxiety scale will be applied. a quiet and calm environment will be provided in the patient room while patients are shown the comedy films. control group: a patient introduction form and a state anxiety scale will be applied as a pre-test before transplant surgery, and vital signs will be checked. no intervention will be made to the control group patients outside of the clinical protocol. after a certain waiting period (average of 30 minutes), the patients' vital signs will be checked and the state anxiety scale will be applied again.

Eligibility criteria:
inclusion criteria: * being over 18 years of age, * being a liver transplant recipient, * data obtained before transplantation, * not having any visual or auditory problems. exclusion criteria: * being under 18 years of age, * having any visual/auditory problems, * not accepting to participate in the study/wanting to leave, * not providing hemodynamic instability (sudden change in vital signs, etc.)

Keywords: stress vital signs pre-operative liver transplant comedy films
prevention and treatment of chronic low back pain through an adapted exercise program

Conditions: Low Back Pain

Summary: objective: the purpose of this study is to investigate the effects of a adapted exercise program and general exercise recommendations compared with only general exercise recommendations for the management of chronic back pain among the workers of bsh (bosch siemens hausgeräte), a manufacturing company.

design: randomized controlled trial. participants: subjects (n_40 volunteers) experimental group (n_20) control group (n_20). all of the participants needs to be diagnosed with chronic back pain by a physician. participants are going to be randomly assigned to two groups: a control group (cg), and experimental group (eg). intervention: the experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application (app) and the app shows specific exercises that the patient needs to practice. the exercise program includes muscle strengthening, flexibility, and endurance training, during 2 months, 3 times/week and generla recommendations. the control group is going to receive only general recommendation (acsm recommendations) with the same kind of mobile application to control the amount of exercise that each patient performs during the week. data on pain intensity (bpi short form, brief pain inventory), disability (oswestry low back pain disability questionnaire), functional assessment of the lumbar spine (emg flexion-relaxation test), amount of weekly physical activity (ipaq), and number of sick leaves are going to be measured immediately before and after intervention and 3 months after the end of the intervention period.

Eligibility criteria:
inclusion criteria: * bsh industry workers. * spine pain diagnosed by a doctor, that has caused a previously sick-leave. the pain does not incapacitate to the patient to perform his job. * in possession of a next-generation mobile. exclusion criteria: * lumbar injury that does not let the patient performs his work or an exercise program.
feasibility study of human umbilical cord tissue-derived mesenchymal stem cells in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: allogeneic human umbilical cord tissue-derived stem cells injected intravenously (iv) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (ms) patients.

the proposed study will assess primarily safety and secondary efficacy endpoints of allogeneic umbilical cord mesenchymal stem cells (uc-msc) administered to 20 patients with ms. the primary objective of the trial is freedom from treatment associated adverse events at 4,12 and 52 weeks post treatment. secondary objective will be efficacy as assessed at baseline, week 12 and 52 and will be quantified based on the following: neurological assessment of the ms functional composite assessment which comprises of expanded disability status scale (edss), the expanded edss (rating neurologic impairment in multiple sclerosis, the scripps neurological rating scale (nrs), paced auditory serial addition test (pasat), the nine-hole peg test, and 25-foot walking time. short-form 36 (sf-36) quality of life questionnaire and gadolinium enhanced mri scans of the brain and cervical spinal cord will also be performed at the indicated time points.

Eligibility criteria:
inclusion criteria: * patients willing to sign informed consent and capable of understanding the features of this clinical trial. * willing to keep a weekly diary and undergo observation for 12 months * non-pregnant patients 18-55 years of age with ms according to the revised mcdonald criteria and meeting the poser criteria for clinically defined ms. * edss scores of 2·0 to 5·5 points assessed at least 3 months after the last acute attack of ms. * must have proof of health insurance in country of residence. exclusion criteria: * patients with evidence of active proliferative retinopathy. * patients with poorly controlled diabetes mellitus (glycated hemoglobin: hba1c \> 8.5%). * patients with renal insufficiency (creatinine\> 2.5) or failure. * infection as evidenced by white blood cell (wbc) count of \>15,000 k/cumm and/or temperature \> 38 celsius. * history of organ transplant. * history of previous or active malignancy, except for localised cutaneous basal or squamous cell carcinoma or carcinoma in situ of the cervix * exercise limiting angina ( canadian cardiovascular society class 3 * congestive heart failure (new york heart association class 3 * unstable angina * acute st elevation myocardial infarction (mi) within 1month * transient ischemic heart attack or stroke within 1 month * severe valvular heart disease

Keywords: multiple sclerosis umbilical cord mesenchymal stem cells
multicenter study on detection strategy of infectious diseases in blood transfusion

Conditions: Infectious Disease Screening

Summary: in the past ten years, nucleic acid detection technology has overcome the limitations of serological detection, reduced missed detections due to window period, occult infection, etc., and its application in the field of pathogen detection has developed rapidly. since 2015, domestic blood collection and supply institutions have fully popularized nucleic acid testing. the safety screening of blood sources mostly adopts the method of combining two times of enzyme-free negative and one time of nucleic acid testing, which excludes the guarantee of blood safety to the greatest extent. at present, the clinical pre-transfusion and pre-operative infectious disease screening in our country is still serological detection. the use of nucleic acid detection for infectious disease screening can better realize the significance of patients' pre-transfusion/pre-operative infectious disease screening. therefore, this study will analyze the nucleic acid detection technology and clinical serological detection technology in order to solve three problems: * explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening; ② explore the confirmation process of the gray area results of infectious disease serological testing; ③ better realize the significance of screening for patients' infectious diseases.


Eligibility criteria:
inclusion criteria: * hosipital patients exclusion criteria: * no

Keywords: nucleic acid pre-transfusion pre-operative pathogen detection
does the addition of hydrogen peroxide to chlorhexidine skin prep to treat p. acnes in the shoulder

Conditions: Propionibacterium Infection

Summary: this is a prospective, randomized controlled trial to evaluate the ability of hydrogen peroxide preparation in addition to chlorhexidine to decrease the colonization of propionibacterium acnes(a bacteria commonly found in the dermis of the skin surrounding the shoulder in order to decrease postoperative joint infection.


Eligibility criteria:
inclusion criteria: 1. all male patients (\>18) undergoing shoulder arthroscopy exclusion criteria: 1. female patients 2. patients with active acne 3. patients who have taken antibiotics within a month of their surgery 4. subjects allergic to any of the following agents: o benzoyl peroxide 5. subjects with psoriatic/eczematous lesions on the shoulder girdle.
impact of gut microbiome on metabolic and bowel function during the first year after spinal cord injury

Conditions: Spinal Cord Injuries; Gut Microbiome

Summary: the investigators will recruit 35 participants with acute sci (within 6 weeks of injury) fasting blood collection and bowel function survey will be conducted 3 times: at baseline \[within 6 weeks of injury\], 6, and 12 months after sci. stool will be collected for gut microbiome analysis 3 times.

stool and fasting blood collection will occur at the rehabilitation hospital (during in-patient stay) and at participants' homes. during the hospital stay, stool will be collected at the bedside by the research team and placed in a para-pak® vial for sample preservation. blood will also be collected by the research team. for sample collection at home, a research nurse will travel to participants home to perform blood draws and bing back to the research lab for processing/analysis/storage. the nurse may also collect the stool sample at the same time as the blood draw if available. if not, participants and their caregivers will be provided with a pre-paid/labeled fedex package containing a stool collection kit (para-pak® vial). prior to bowel movement, participants and caregivers will be asked to clean the anal area using the sanitizing wipes; approximately 5-10 ml of stool will be transferred to the para-pak® vial using the attached spatula in the para-pak® vial. for participants who conduct their bowel management program in their beds, an additional sterile absorbent pad will be provided to use as a barrier between the bed and the participant to limit contamination. fedex package containing the stool sample will be shipped to the investigators' lab for each participant, the investigators will record 1) diet (via 24-hour dietary recalls), 2) physical activity habits (via the rehabilitation therapies survey included in the sci common data elements \[cdes\], 3)leisure time physical activity questionnaire; 4)depression and anxiety (via patient health questionnaire-9 \[phq9\] and the general anxiety disorder-7 scale (gad7),respectively); 5)prescribed medications, including antibiotics (via redcap platform); 6)use of supplements and bowel routine components, including probiotics and laxatives (via self-report); and 7)any other comorbidities beyond gi dysfunction

Eligibility criteria:
inclusion criteria: 1. 18-85 years of age 2. diagnosis of traumatic sci at the cervical to lumbar level (c3-l2) 3. classification of a, b, c (motor complete, incomplete). exclusion criteria: 1. women who are pregnant prior to consent 2. neurological impairment other than sci 3. self-reported history of crohn's disease or diverticulitis 4. irritable bowel syndrome 5. gastric blockage/obstruction or swallowing disorder 6. prior gi surgery 7. intrathecal pump 8. concurrent usage of functional electrical stimulation for bowel management (e.g., constipation). 9. able to ambulate

Keywords: sci inflammation bowel function blood sugar lipid profiles
dietary treatment for ibs within primary health care

Conditions: Irritable Bowel Syndrome

Summary: irritable bowel syndrome (ibs) is a multifaceted disorder where diet plays a pivotal role in symptom generation and management. the traditional dietary advice given to patients in clinical settings are based on the nice guidelines. some of the advice included in these guidelines have limited scientific evidence. the aim of this study is to investigate the effectiveness of the traditional dietary advice in ibs, according to the nice guidelines, within a primary health care setting, where treatment is delivered digitally and in groups of 8-12 individuals. as a sham comparator, one group will receive dietary advice according to the swedish dietary guidelines regarding healthy eating habits.


Eligibility criteria:
inclusion criteria: * diagnosed with ibs (rome iv) by physician * age 18-50 * ability to read and understand swedish * signed informed consent exclusion criteria: * received dietary treatment for ibs previously * manifestations of other conditions that may explain gastrointestinal symptoms
masitinib in combination with gemcitabine in advanced/metastatic epithelial ovarian cancer patients

Conditions: Ovarian Cancer

Summary: the objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.

masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. the objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine as compared with single agent gemcitabine in advanced or metastatic epithelial ovarian cancer patients who are refractory to platinum treatment. this is an open-label, randomized, active-controlled, phase 2/3 study. the study's primary efficacy measure will be overall survival. masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal. the study design is a two-stage adaptive design, meaning that it includes a prospectively planned opportunity for modification of one or more specified aspects of the study (for example patient enrollment).

Eligibility criteria:
main inclusion criteria: 1. female patient, with histologically or cytologically confirmed advanced / metastatic epithelial ovarian cancer (including primary peritoneal and primary fallopian tube cancer), which is either: * first line platinum-refractory ovarian cancer (progression during first-line platinum-based chemotherapy) * first line platinum-resistant ovarian cancer (relapsing within 6 months after the end of first-line chemotherapy); * candidate to third line of treatment (refractory, resistant, or sensitive to 2nd line platinum-based therapy or patients who progressed after other type of chemotherapy in 2nd line). 2. patient with adequate organ function per laboratory tests evaluations main exclusion criteria: 1. patient intolerant to gemcitabine 2. patient who has not recovered from any significant treatment toxicities prior to baseline (≥grade 2) 3. pregnant or nursing female patient

Keywords: ovarian cancer tyrosine kinase inhibitor
analysis of lung cancer tissue with spatial frequency domain imaging

Conditions: Lung Diseases; Cancer, Lung

Summary: this study investigates if a new imaging device can detect different types of lung tissue using spatial frequency domain imaging (sfdi). specifically, this study aims to detect lung nodules within normal lung tissue and determine if lung nodules are cancerous. patients who have confirmed or suspected lung nodules and who are undergoing resection of those nodules will be recruited for the study. study participants will undergo standard of care lung nodule resection in the operating room, and the resected specimen will be imaged using the sfdi device immediately after removal from the surgical field. the data captured from the sfdi images will then be compared to the pathology findings to identify optical properties of normal and cancerous lung tissue. because the intervention is conducted on resected biospecimens, this study yields minimal risk to participants.


Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years old * suspected or confirmed lung nodule on diagnostic imaging * undergoing lung resection using an open, endoscopic, or robotic approach * standard of care orders placed for a pathology assessment of resected lung tissue * adults undergoing lung resection for a lung mass exclusion criteria: * \<18 years old * pregnant females and incarcerated individuals * no standard of care orders to obtain a pathology assessment * rush pathology order for resected lung tissue * any condition where the principal investigator determines to impact patient safety or quality of care
a clinical study of mass balance of [14c]hrs-7535

Conditions: Type 2 Diabetes Mellitus; Weight Loss

Summary: the objective is to evaluate the mass balance of \[14c\]hrs-7535 in healthy adult chinese subjects.


Eligibility criteria:
inclusion criteria: 1. subjects must voluntarily sign the informed consent form (icf) prior to any activities related to the study, demonstrate understanding of the study procedures and methods, and commit to strictly adhering to the clinical trial protocol to complete the study. 2. healthy male subjects aged between 18 and 45 years (inclusive), determined at the time of signing the informed consent. 3. male subjects must weigh ≥ 50 kg and have a body mass index (bmi) between 19 and 26 kg/m² (inclusive). 4. male subjects with female partners of childbearing potential must have no plans for procreation or sperm donation from the time of signing the informed consent until one year after the last dose of the study drug. they must also agree to use highly effective contraception methods (including their partners) during this period. exclusion criteria: 1. subjects with abnormalities identified through a comprehensive physical examination, vital signs assessment, laboratory tests, chest x-ray, 12-lead ecg, or abdominal ultrasound that are deemed clinically significant by the investigator. 2. subjects with qtcf ≥ 450 msec at screening or baseline, or any other abnormalities considered clinically significant by the investigator. 3. subjects who test positive for hepatitis b surface antigen (hbsag), anti-hepatitis c virus (hcv) antibodies, human immunodeficiency virus (hiv) antigen/antibody combination, or syphilis-specific antibodies. 4. subjects with a history of drug abuse, drug dependence (based on medical history), or those who test positive for drug abuse during urine screening prior to dosing. 5. subjects who have used any prescription drugs, over-the-counter medications, herbal medicines, or dietary supplements within 2 weeks prior to screening.
hereditary risk factors for thyroid cancer

Conditions: Thyroid Cancer

Summary: thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules. * in this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies. * individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.

the purpose of this research study is to learn more about risk factors for inherited thyroid cancer. the investigators would like to use the participant dna to look for alterations in genes. the investigator will perform dna sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.

Eligibility criteria:
inclusion criteria: * individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s). * individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below). * individuals from families with a high suspicion of hereditary thyroid cancer: * families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (\<18 years old). * families with a high suspicion of hereditary thyroid cancer/nodules other than above to include: * families with thyroid cancer in multiple individuals * families with thyroid cancer and a known genetic syndrome * families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.) exclusion criteria: * individuals who are unable to give informed consent. * individuals who are unable to complete study materials.

Keywords: thyroid
ocular comfort and inflammation in lid hygiene therapy

Conditions: Blepharitis

Summary: the primary study objectives are: to evaluate (1) the change in ocular discomfort at 30 days and (2) the change in signs and symptoms of ocular surface disease in demodex-positive subjects beginning the use of avenova.

this is a prospective study of subjects who have been diagnosed with bilateral demodex blepharitis. qualified symptomatic eyes will be randomized and monitored for 30 days; one eye will undergo avenova treatment twice daily and one eye will not undergo any study treatment.

Eligibility criteria:
inclusion criteria: * subject signed and dated a irb-approved informed consent document * mild or greater demodex (minimum 15 observable mites in six lashes) * score of 20 or more on the osdi questionnaire * score of 20 or more on the eyelid inflammation questionnaire exclusion criteria: * currently enrolled in another prospective research study * unable to attend two follow-up visits over 30 days * current allergic conjunctivitis of the cornea, conjunctiva, or eyelid in either eye * prior ocular trauma where surgery was indicated * prior corneal transplant in either eye * any ocular surgery within the past six months * abnormal corneal scarring, erosions, or stevens-johnson syndrome * anticipation of ocular surgery within the next 30 days * non-english speaking * pregnant, nursing, or expect to become pregnant within the next 30 days * known sensitivity to chlorine or avenova * moderate, or severe conjunctivochalasis * contact lenses within the last 30 days and unwilling to discontinue for 30 days * use of topical cyclosporine for less than 6 continuous months prior to baseline * procedure such as pulsed light or commercial lid massage in last 30 days * known history of autoimmune disease * punctal plugs placed within the last 30 days * use of avenova or other lid cleansers within the last 30 days * changes in systemic or ocular medications in the last 30 days * unwilling to commit to the same ocular and systemic medications for 30 days